Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer

Cancer Res (2025) 85 (10): 1888–1908.

https://doi.org/10.1158/0008-5472.CAN-24-2531

Published: 15 May 2025

View articletitled, Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract CT093: Cancer Core Europe - Basket of Baskets - first results from module 1: Atezolizumab in genomically selected populations

Irene Brana, Christophe Massard, Frans Opdam, Richard D. Baird, Luigi De Petris, Richard Schlenk, Claudio Vernieri, David Tamborero, Shubha Anand, Etienne Rouleau, Adria Lopez, Nikos Demiris, Paolo Nuciforo, Elena Provenzano, Daniel Huebschmann, Katrin Pfütze, Maria Pernemalm, Daniel Vis, Ana Vivancos, Valtteri Wirta, Peter Horak, Omar Saavedra, Marloes van Dongen, Emily Barker, Susana Aguilar, Elena Chavarria, Xenia Villalobos, Marta Rotxes, Arantxa Romero, Francisco Martínez-Jiménez, Alena Gros, Anna Pedrola, Cristina Viaplana, Neeltje Steeghs, Elena Garralda, Cancer Core Europe - Basket of Baskets study team, Alejandro Piris, Karim Fizazi, Fabrice Barlesi, Karen Barker, Michiel Heijden, Wilbert Zwart, Filippo de Braud, Elias Arner, Janne Lehtiö, Michael Baumann, Stefan Fröhling, Josep Tabernero, Javier Carmona, Jordi Rodon

Cancer Res (2025) 85 (8_Supplement_2): CT093.

https://doi.org/10.1158/1538-7445.AM2025-CT093

Published: 25 April 2025

View articletitled, Abstract CT093: Cancer Core Europe - Basket of Baskets - first results from module 1: Atezolizumab in genomically selected populations

Journal Articles

Abstract P1-05-14: ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER

Cancer Res (2023) 83 (5_Supplement): P1-05-14.

https://doi.org/10.1158/1538-7445.SABCS22-P1-05-14

Published: 01 March 2023

View articletitled, Abstract P1-05-14: ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER

Journal Articles

Abstract 1229: miRNA and response to trastuzumab

Cancer Res (2022) 82 (12_Supplement): 1229.

https://doi.org/10.1158/1538-7445.AM2022-1229

Published: 15 June 2022

View articletitled, Abstract 1229: miRNA and response to trastuzumab

Journal Articles

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Res (2022) 82 (8): 1646–1657.

https://doi.org/10.1158/0008-5472.CAN-21-2409

Published: 15 April 2022

View articletitled, Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Includes: Supplementary data

Journal Articles

Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)

Meritxell Bellet, Serafin Morales, Ariadna Gasol, Kepa Amillano, Nuria Chic, Xavier González-Farré, Patricia Villagrasa, Laia Paré, Claudette Falato, Paolo Nuciforo, Débora Martínez, Juan M Ferrero-Cafiero, Tomás Pascual, Aleix Prat, Carol Lange, Cristina Saura

Cancer Res (2022) 82 (4_Supplement): P1-07-02.

https://doi.org/10.1158/1538-7445.SABCS21-P1-07-02

Published: 15 February 2022

View articletitled, Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)

Journal Articles

Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study

Cancer Res (2022) 82 (4_Supplement): PD8-03.

https://doi.org/10.1158/1538-7445.SABCS21-PD8-03

Published: 15 February 2022

View articletitled, Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study

Journal Articles

Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial

Cancer Res (2022) 82 (4_Supplement): PD5-05.

https://doi.org/10.1158/1538-7445.SABCS21-PD5-05

Published: 15 February 2022

View articletitled, Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial

Journal Articles

Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study

Cancer Res (2022) 82 (4_Supplement): P2-13-12.

https://doi.org/10.1158/1538-7445.SABCS21-P2-13-12

Published: 15 February 2022

View articletitled, Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study

Journal Articles

Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study

Cancer Res (2022) 82 (4_Supplement): P5-13-26.

https://doi.org/10.1158/1538-7445.SABCS21-P5-13-26

Published: 15 February 2022

View articletitled, Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study

Journal Articles

Abstract PS5-13: Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA

Enzo Batistella, Laia Paré, Mihir Sahasrabudhe, Tomás Pascual, Maria Vakalopoulou, Patricia Villagrasa, Eric Deutsch, Núria Chic, Guillermo Villacampa, Paolo Nuciforo, Javier Cortes, Antonio Llombart-Cussac, Nikos Paragios, Aleix Prat

Cancer Res (2021) 81 (4_Supplement): PS5-13.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-13

Published: 15 February 2021

View articletitled, Abstract PS5-13: Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA

Journal Articles

Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Nuria Chic, Stephen Luen, Paolo Nuciforo, Roberto Salgado, Debora Fumagalli, Florentine Hilbers, Yingbo Wang, Evandro de Azambuja, Itsvan Lang, Serena Di Cosimo, Cristina Saura, Jens Huober, Aleix Prat, Sherene Loi

Cancer Res (2021) 81 (4_Supplement): PS5-03.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-03

Published: 15 February 2021

View articletitled, Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Journal Articles

Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial

Cancer Res (2020) 80 (16_Supplement): 1998.

https://doi.org/10.1158/1538-7445.AM2020-1998

Published: 15 August 2020

View articletitled, Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial

Journal Articles

Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

Matthew J Wongchenko, Mafalda Oliveira, Cristina Saura, Paolo Nuciforo, Isabel Calvo, Jay Andersen, José L Passos Coelho, Miguel Gil Gil, Begoña Bermejo, Debra A Patt, Eva Ciruelos, Zhen Shi, Na Xu, Patricia Villagrasa, Aruna Mani, Steven J Isakoff

Cancer Res (2020) 80 (4_Supplement): P4-10-23.

https://doi.org/10.1158/1538-7445.SABCS19-P4-10-23

Published: 15 February 2020

View articletitled, Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

Journal Articles

Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

Zhen Shi, Steven J. Isakoff, Cristina Saura, Paolo Nuciforo, Isabel Calvo, Jay Andersen, José Luis Passos Coelho, Miguel Gil Gil, Begoña Bermejo, Debra A. Patt, Eva Ciruelos, Matthew J. Wongchenko, Stina M. Singel, Na Xu, Lorena de la Peña, José Baselga, Steven Gendreau, Mafalda Oliveira

Cancer Res (2019) 79 (13_Supplement): 4891.

https://doi.org/10.1158/1538-7445.AM2019-4891

Published: 01 July 2019

View articletitled, Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

Journal Articles

Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347

Anthony J. Iafrate, Darrell R. Borger, Ana Vivancos, Martin Voss, James Cleary, Funda Meric-Bernstam, Josep Tabernero, Keith Flaherty, Nobuya Ishii, Franck Brichory, Hiroaki Tanaka, Anna Pokorska-Bocci, Jose Baselga, Paolo Nuciforo

Cancer Res (2019) 79 (13_Supplement): 4881.

https://doi.org/10.1158/1538-7445.AM2019-4881

Published: 01 July 2019

View articletitled, Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347

Journal Articles

Abstract 5129: Fusobacterium and co-occurring microbes in primary and metastatic colorectal cancer

Susan Bullman, Chandra S. Pedamallu, Ewa Sicinska, Thomas Clancy, Shuji Ogino, Josep Tabernero, Charles Fuchs, William C. Hahn, Paolo Nuciforo, Matthew Meyerson

Cancer Res (2018) 78 (13_Supplement): 5129.

https://doi.org/10.1158/1538-7445.AM2018-5129

Published: 01 July 2018

View articletitled, Abstract 5129: Fusobacterium and co-occurring microbes in primary and metastatic colorectal cancer

Journal Articles

Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment

Cancer Res (2018) 78 (13_Supplement): LB-292.

https://doi.org/10.1158/1538-7445.AM2018-LB-292

Published: 01 July 2018

View articletitled, Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment

Journal Articles

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Cancer Res (2017) 77 (13): 3540–3550.

https://doi.org/10.1158/0008-5472.CAN-16-3556

Published: 02 July 2017

View articletitled, Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Includes: Supplementary data

Journal Articles

Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression

Franck Brichory, Anna Pokorska-Bocci, Paolo Nuciforo, Stefania Rigotti, Nathalie Lembrez, Grégoire Vuagniaux, Corinne Moulon, Anne Vaslin

Cancer Res (2017) 77 (13_Supplement): 2088.

https://doi.org/10.1158/1538-7445.AM2017-2088

Published: 01 July 2017

View articletitled, Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer

Abstract CT093: Cancer Core Europe - Basket of Baskets - first results from module 1: Atezolizumab in genomically selected populations

Abstract P1-05-14: ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER

Abstract 1229: miRNA and response to trastuzumab

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)

Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study

Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial

Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study

Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study

Abstract PS5-13: Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA

Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial

Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347

Abstract 5129: Fusobacterium and co-occurring microbes in primary and metastatic colorectal cancer

Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only